RU2000110744A - Heteroaryl diazacycloalkanes as cholinergic ligands for nicotinic acetylcholine receptors - Google Patents
Heteroaryl diazacycloalkanes as cholinergic ligands for nicotinic acetylcholine receptorsInfo
- Publication number
- RU2000110744A RU2000110744A RU2000110744/04A RU2000110744A RU2000110744A RU 2000110744 A RU2000110744 A RU 2000110744A RU 2000110744/04 A RU2000110744/04 A RU 2000110744/04A RU 2000110744 A RU2000110744 A RU 2000110744A RU 2000110744 A RU2000110744 A RU 2000110744A
- Authority
- RU
- Russia
- Prior art keywords
- pyridyl
- homopiperazine
- methyl
- piperazine
- methoxy
- Prior art date
Links
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 title claims 3
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 title claims 3
- 230000027455 binding Effects 0.000 title 1
- 230000001713 cholinergic Effects 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- -1 aminophenyl Chemical group 0.000 claims 88
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims 30
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 229920000728 polyester Polymers 0.000 claims 6
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 230000002093 peripheral Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000000051 modifying Effects 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- OXCIHVBAXPHXPZ-UHFFFAOYSA-N 1-methyl-4-pyridin-3-yl-1,4-diazepane Chemical compound C1CN(C)CCCN1C1=CC=CN=C1 OXCIHVBAXPHXPZ-UHFFFAOYSA-N 0.000 claims 2
- HBWGDGHGYGHWKD-UHFFFAOYSA-N 1-methyl-4-pyridin-3-ylpiperazine Chemical compound C1CN(C)CCN1C1=CC=CN=C1 HBWGDGHGYGHWKD-UHFFFAOYSA-N 0.000 claims 2
- JBOVXXZNZSULJJ-UHFFFAOYSA-N 1-pyridin-3-yl-1,4-diazepane Chemical compound C1CCNCCN1C1=CC=CN=C1 JBOVXXZNZSULJJ-UHFFFAOYSA-N 0.000 claims 2
- DNDJHEWLYGJJCY-UHFFFAOYSA-N 1-pyridin-3-ylpiperazine Chemical compound C1CNCCN1C1=CC=CN=C1 DNDJHEWLYGJJCY-UHFFFAOYSA-N 0.000 claims 2
- 125000001331 3-methylbutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 2
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 125000006501 nitrophenyl group Chemical group 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 230000005586 smoking cessation Effects 0.000 claims 2
- 230000016160 smooth muscle contraction Effects 0.000 claims 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 claims 1
- CXPUAWQOXQINEX-UHFFFAOYSA-N 1,4-diazocane Chemical compound C1CCNCCNC1 CXPUAWQOXQINEX-UHFFFAOYSA-N 0.000 claims 1
- HTSQWLLKIZBMEO-UHFFFAOYSA-N 1,5-diazocane Chemical compound C1CNCCCNC1 HTSQWLLKIZBMEO-UHFFFAOYSA-N 0.000 claims 1
- BINPOEPJNVMNPQ-UHFFFAOYSA-N 1-(3-methoxyphenyl)-1,4-diazepane Chemical compound COC1=CC=CC(N2CCNCCC2)=C1 BINPOEPJNVMNPQ-UHFFFAOYSA-N 0.000 claims 1
- IZXOFIZUDVFRNW-UHFFFAOYSA-N 1-(3-nitrophenyl)-1,4-diazepane Chemical compound [O-][N+](=O)C1=CC=CC(N2CCNCCC2)=C1 IZXOFIZUDVFRNW-UHFFFAOYSA-N 0.000 claims 1
- LUAQATCGUQIPIE-UHFFFAOYSA-N 1-(5,6-dimethoxypyridin-3-yl)-1,4-diazepane Chemical compound N1=C(OC)C(OC)=CC(N2CCNCCC2)=C1 LUAQATCGUQIPIE-UHFFFAOYSA-N 0.000 claims 1
- XLVXXHDLCCVVLU-UHFFFAOYSA-N 1-(5-bromopyridin-3-yl)-1,4-diazepane Chemical compound BrC1=CN=CC(N2CCNCCC2)=C1 XLVXXHDLCCVVLU-UHFFFAOYSA-N 0.000 claims 1
- PCYDWDFYQBRLLS-UHFFFAOYSA-N 1-(5-butoxypyridin-3-yl)-1,4-diazepane Chemical compound CCCCOC1=CN=CC(N2CCNCCC2)=C1 PCYDWDFYQBRLLS-UHFFFAOYSA-N 0.000 claims 1
- HXIKXVVKUJGTHI-UHFFFAOYSA-N 1-(5-butoxypyridin-3-yl)-4-methyl-1,4-diazepane Chemical compound CCCCOC1=CN=CC(N2CCN(C)CCC2)=C1 HXIKXVVKUJGTHI-UHFFFAOYSA-N 0.000 claims 1
- XBBDTUVYONBPML-UHFFFAOYSA-N 1-(5-butoxypyridin-3-yl)-4-methylpiperazine Chemical compound CCCCOC1=CN=CC(N2CCN(C)CC2)=C1 XBBDTUVYONBPML-UHFFFAOYSA-N 0.000 claims 1
- NAWZJYYROXFASI-UHFFFAOYSA-N 1-(5-butoxypyridin-3-yl)piperazine Chemical compound CCCCOC1=CN=CC(N2CCNCC2)=C1 NAWZJYYROXFASI-UHFFFAOYSA-N 0.000 claims 1
- BSLASFXFWLBNMK-UHFFFAOYSA-N 1-(5-chloropyridin-3-yl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CN=CC(Cl)=C1 BSLASFXFWLBNMK-UHFFFAOYSA-N 0.000 claims 1
- MYRHBCKCPROFGA-UHFFFAOYSA-N 1-(5-chloropyridin-3-yl)piperazine Chemical compound ClC1=CN=CC(N2CCNCC2)=C1 MYRHBCKCPROFGA-UHFFFAOYSA-N 0.000 claims 1
- SYSCGYLNJIYMGG-UHFFFAOYSA-N 1-(5-cyclopentyloxypyridin-3-yl)-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1C1=CN=CC(OC2CCCC2)=C1 SYSCGYLNJIYMGG-UHFFFAOYSA-N 0.000 claims 1
- DWHQCXVYIKBENZ-UHFFFAOYSA-N 1-(5-ethenoxypyridin-3-yl)-1,4-diazepane Chemical compound C=COC1=CN=CC(N2CCNCCC2)=C1 DWHQCXVYIKBENZ-UHFFFAOYSA-N 0.000 claims 1
- YNPFRHMMMCCESU-UHFFFAOYSA-N 1-(5-ethenoxypyridin-3-yl)-1,5-diazocane Chemical compound C=COC1=CN=CC(N2CCCNCCC2)=C1 YNPFRHMMMCCESU-UHFFFAOYSA-N 0.000 claims 1
- WJRSMYHTWOUBAZ-UHFFFAOYSA-N 1-(5-ethenoxypyridin-3-yl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CN=CC(OC=C)=C1 WJRSMYHTWOUBAZ-UHFFFAOYSA-N 0.000 claims 1
- VBUZMQUXIQZALI-UHFFFAOYSA-N 1-(5-ethenoxypyridin-3-yl)piperazine Chemical compound C=COC1=CN=CC(N2CCNCC2)=C1 VBUZMQUXIQZALI-UHFFFAOYSA-N 0.000 claims 1
- UKUOBODWAQBJIE-UHFFFAOYSA-N 1-(5-ethoxypyridin-3-yl)-1,5-diazocane Chemical compound CCOC1=CN=CC(N2CCCNCCC2)=C1 UKUOBODWAQBJIE-UHFFFAOYSA-N 0.000 claims 1
- CIODFWCOPNEEQH-UHFFFAOYSA-N 1-(5-ethoxypyridin-3-yl)-4-ethylpiperazine Chemical compound CCOC1=CN=CC(N2CCN(CC)CC2)=C1 CIODFWCOPNEEQH-UHFFFAOYSA-N 0.000 claims 1
- SXZCIPTVUFDPIG-UHFFFAOYSA-N 1-(5-ethoxypyridin-3-yl)-4-methyl-1,4-diazepane Chemical compound CCOC1=CN=CC(N2CCN(C)CCC2)=C1 SXZCIPTVUFDPIG-UHFFFAOYSA-N 0.000 claims 1
- SSBJALIOWHKFQD-UHFFFAOYSA-N 1-(5-ethoxypyridin-3-yl)-4-methylpiperazine Chemical compound CCOC1=CN=CC(N2CCN(C)CC2)=C1 SSBJALIOWHKFQD-UHFFFAOYSA-N 0.000 claims 1
- OAKPVSOBMJGPSZ-UHFFFAOYSA-N 1-(5-ethoxypyridin-3-yl)piperazine Chemical compound CCOC1=CN=CC(N2CCNCC2)=C1 OAKPVSOBMJGPSZ-UHFFFAOYSA-N 0.000 claims 1
- CTMLEMJMYZMVFW-UHFFFAOYSA-N 1-(5-ethynylpyridin-3-yl)-1,4-diazepane Chemical compound C#CC1=CN=CC(N2CCNCCC2)=C1 CTMLEMJMYZMVFW-UHFFFAOYSA-N 0.000 claims 1
- XYAQZUBGSRIWRI-UHFFFAOYSA-N 1-(5-heptoxypyridin-3-yl)-1,4-diazepane Chemical compound CCCCCCCOC1=CN=CC(N2CCNCCC2)=C1 XYAQZUBGSRIWRI-UHFFFAOYSA-N 0.000 claims 1
- SKBJCLBMYVXUAC-UHFFFAOYSA-N 1-(5-heptoxypyridin-3-yl)-4-methyl-1,4-diazepane Chemical compound CCCCCCCOC1=CN=CC(N2CCN(C)CCC2)=C1 SKBJCLBMYVXUAC-UHFFFAOYSA-N 0.000 claims 1
- UHOWIRLRFQDWDJ-UHFFFAOYSA-N 1-(5-hexoxypyridin-3-yl)-1,4-diazepane Chemical compound CCCCCCOC1=CN=CC(N2CCNCCC2)=C1 UHOWIRLRFQDWDJ-UHFFFAOYSA-N 0.000 claims 1
- QPKJBGOPBKHVNR-UHFFFAOYSA-N 1-(5-hexoxypyridin-3-yl)-4-methyl-1,4-diazepane Chemical compound CCCCCCOC1=CN=CC(N2CCN(C)CCC2)=C1 QPKJBGOPBKHVNR-UHFFFAOYSA-N 0.000 claims 1
- DUYJXRYZJHFTFB-UHFFFAOYSA-N 1-(5-methoxypyridin-3-yl)-1,3-diazinane Chemical compound COC1=CN=CC(N2CNCCC2)=C1 DUYJXRYZJHFTFB-UHFFFAOYSA-N 0.000 claims 1
- CLRANNZHQRADST-UHFFFAOYSA-N 1-(5-methoxypyridin-3-yl)-1,4-diazepane Chemical compound COC1=CN=CC(N2CCNCCC2)=C1 CLRANNZHQRADST-UHFFFAOYSA-N 0.000 claims 1
- SHALYUZFJLUFSL-UHFFFAOYSA-N 1-(5-methoxypyridin-3-yl)-1,5-diazocane Chemical compound COC1=CN=CC(N2CCCNCCC2)=C1 SHALYUZFJLUFSL-UHFFFAOYSA-N 0.000 claims 1
- UQIGCWXXDZIAON-UHFFFAOYSA-N 1-(5-methoxypyridin-3-yl)-4-methyl-1,4-diazepane Chemical compound COC1=CN=CC(N2CCN(C)CCC2)=C1 UQIGCWXXDZIAON-UHFFFAOYSA-N 0.000 claims 1
- YZZHDBRZZYHVJG-UHFFFAOYSA-N 1-(5-methoxypyridin-3-yl)-4-methyl-1,5-diazocane Chemical compound COC1=CN=CC(N2CCC(C)NCCC2)=C1 YZZHDBRZZYHVJG-UHFFFAOYSA-N 0.000 claims 1
- MCAJKSUXVCBTTP-UHFFFAOYSA-N 1-(5-methoxypyridin-3-yl)-4-methylpiperazine Chemical compound COC1=CN=CC(N2CCN(C)CC2)=C1 MCAJKSUXVCBTTP-UHFFFAOYSA-N 0.000 claims 1
- HSIGWPYNPCNTCE-UHFFFAOYSA-N 1-(5-methoxypyridin-3-yl)piperazine Chemical compound COC1=CN=CC(N2CCNCC2)=C1 HSIGWPYNPCNTCE-UHFFFAOYSA-N 0.000 claims 1
- IWYDMTKGIWVZES-UHFFFAOYSA-N 1-(5-pentoxypyridin-3-yl)-1,4-diazepane Chemical compound CCCCCOC1=CN=CC(N2CCNCCC2)=C1 IWYDMTKGIWVZES-UHFFFAOYSA-N 0.000 claims 1
- UTJLUZMSRMFBNA-UHFFFAOYSA-N 1-(5-phenylpyridin-3-yl)piperazine Chemical compound C1CNCCN1C1=CN=CC(C=2C=CC=CC=2)=C1 UTJLUZMSRMFBNA-UHFFFAOYSA-N 0.000 claims 1
- LWFPJCHDKSLKOQ-UHFFFAOYSA-N 1-(5-propoxypyridin-3-yl)-1,4-diazepane Chemical compound CCCOC1=CN=CC(N2CCNCCC2)=C1 LWFPJCHDKSLKOQ-UHFFFAOYSA-N 0.000 claims 1
- RBVFSVQTEMGOJK-UHFFFAOYSA-N 1-(5-propoxypyridin-3-yl)-1,5-diazocane Chemical compound CCCOC1=CN=CC(N2CCCNCCC2)=C1 RBVFSVQTEMGOJK-UHFFFAOYSA-N 0.000 claims 1
- KANJHLBZMCYLFW-UHFFFAOYSA-N 1-(5-thiophen-2-ylpyridin-3-yl)-1,4-diazepane Chemical compound C1CCNCCN1C1=CN=CC(C=2SC=CC=2)=C1 KANJHLBZMCYLFW-UHFFFAOYSA-N 0.000 claims 1
- UGNNTIXQGYYUAP-UHFFFAOYSA-N 1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane Chemical compound N1=C(Br)C(OCC)=CC(N2CCNCCC2)=C1 UGNNTIXQGYYUAP-UHFFFAOYSA-N 0.000 claims 1
- JRNYLCIPPWHNEJ-UHFFFAOYSA-N 1-(6-bromopyridin-3-yl)-1,4-diazepane Chemical compound C1=NC(Br)=CC=C1N1CCNCCC1 JRNYLCIPPWHNEJ-UHFFFAOYSA-N 0.000 claims 1
- JKEGBHGSFLQXTK-UHFFFAOYSA-N 1-(6-chloropyridazin-3-yl)-1,4-diazocane Chemical compound N1=NC(Cl)=CC=C1N1CCNCCCC1 JKEGBHGSFLQXTK-UHFFFAOYSA-N 0.000 claims 1
- ZZKUFGQEEULRGN-UHFFFAOYSA-N 1-(6-chloropyridazin-3-yl)-1,5-diazocane Chemical compound N1=NC(Cl)=CC=C1N1CCCNCCC1 ZZKUFGQEEULRGN-UHFFFAOYSA-N 0.000 claims 1
- LRAQITPFWFDXRM-UHFFFAOYSA-N 1-(6-chloropyridazin-3-yl)-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1C1=CC=C(Cl)N=N1 LRAQITPFWFDXRM-UHFFFAOYSA-N 0.000 claims 1
- QCPZSUGVUNQGEG-UHFFFAOYSA-N 1-(6-chloropyridazin-3-yl)-4-methyl-1,5-diazocane Chemical compound C1CCNC(C)CCN1C1=CC=C(Cl)N=N1 QCPZSUGVUNQGEG-UHFFFAOYSA-N 0.000 claims 1
- COTNBIFZSPMJRS-UHFFFAOYSA-N 1-(6-chloropyridin-3-yl)-1,4-diazepane Chemical compound C1=NC(Cl)=CC=C1N1CCNCCC1 COTNBIFZSPMJRS-UHFFFAOYSA-N 0.000 claims 1
- NDMXANRHRVRLQR-UHFFFAOYSA-N 1-(6-pyrrolidin-1-ylpyridin-3-yl)-1,4-diazepane Chemical compound C1CCCN1C1=CC=C(N2CCNCCC2)C=N1 NDMXANRHRVRLQR-UHFFFAOYSA-N 0.000 claims 1
- YVYLKKKASVLYEK-UHFFFAOYSA-N 1-[5-(2-ethoxyethoxy)pyridin-3-yl]-1,4-diazepane Chemical compound CCOCCOC1=CN=CC(N2CCNCCC2)=C1 YVYLKKKASVLYEK-UHFFFAOYSA-N 0.000 claims 1
- SIPSUTQRUBWRRD-UHFFFAOYSA-N 1-[5-(2-methoxyethoxy)pyridin-3-yl]-1,4-diazepane Chemical compound COCCOC1=CN=CC(N2CCNCCC2)=C1 SIPSUTQRUBWRRD-UHFFFAOYSA-N 0.000 claims 1
- RPXRPEUOPRESKS-UHFFFAOYSA-N 1-[5-(2-methoxyethoxy)pyridin-3-yl]-4-methyl-1,4-diazepane Chemical compound COCCOC1=CN=CC(N2CCN(C)CCC2)=C1 RPXRPEUOPRESKS-UHFFFAOYSA-N 0.000 claims 1
- BIVCEXLTKFTSNE-UHFFFAOYSA-N 1-[5-(2-methylpropoxy)pyridin-3-yl]-1,4-diazepane Chemical compound CC(C)COC1=CN=CC(N2CCNCCC2)=C1 BIVCEXLTKFTSNE-UHFFFAOYSA-N 0.000 claims 1
- RSRCMOHGADYDIP-UHFFFAOYSA-N 1-[5-(3-methylbutoxy)pyridin-3-yl]-1,4-diazepane Chemical compound CC(C)CCOC1=CN=CC(N2CCNCCC2)=C1 RSRCMOHGADYDIP-UHFFFAOYSA-N 0.000 claims 1
- WMLBSRGFLMYCRL-UHFFFAOYSA-N 1-[5-(cyclohexylmethoxy)pyridin-3-yl]-1,4-diazepane Chemical compound C1CCCCC1COC(C=1)=CN=CC=1N1CCCNCC1 WMLBSRGFLMYCRL-UHFFFAOYSA-N 0.000 claims 1
- BQKVPHLADFCQMM-UHFFFAOYSA-N 1-[5-(cyclohexylmethoxy)pyridin-3-yl]-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1C1=CN=CC(OCC2CCCCC2)=C1 BQKVPHLADFCQMM-UHFFFAOYSA-N 0.000 claims 1
- NTVHYTYHYIGUSQ-UHFFFAOYSA-N 1-[5-(cyclopropylmethoxy)pyridin-3-yl]-1,4-diazepane Chemical compound C1CC1COC(C=1)=CN=CC=1N1CCCNCC1 NTVHYTYHYIGUSQ-UHFFFAOYSA-N 0.000 claims 1
- XFKDCCSPHQFITP-UHFFFAOYSA-N 1-[5-(cyclopropylmethoxy)pyridin-3-yl]-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1C1=CN=CC(OCC2CC2)=C1 XFKDCCSPHQFITP-UHFFFAOYSA-N 0.000 claims 1
- XSZHQYYEDXHKHO-UHFFFAOYSA-N 1-[5-(trifluoromethyl)pyridin-3-yl]-1,4-diazepane Chemical compound FC(F)(F)C1=CN=CC(N2CCNCCC2)=C1 XSZHQYYEDXHKHO-UHFFFAOYSA-N 0.000 claims 1
- KZNRJQVKHPDDHZ-UHFFFAOYSA-N 1-benzyl-4-pyridin-3-yl-1,4-diazepane Chemical compound C=1C=CC=CC=1CN(CC1)CCCN1C1=CC=CN=C1 KZNRJQVKHPDDHZ-UHFFFAOYSA-N 0.000 claims 1
- OJLZKNXSWYJFRQ-UHFFFAOYSA-N 1-ethyl-4-pyridin-3-yl-1,4-diazepane Chemical compound C1CN(CC)CCCN1C1=CC=CN=C1 OJLZKNXSWYJFRQ-UHFFFAOYSA-N 0.000 claims 1
- HBYXTRBRSLAGLN-UHFFFAOYSA-N 1-methyl-4-(5-phenylpyridin-3-yl)piperazine Chemical compound C1CN(C)CCN1C1=CN=CC(C=2C=CC=CC=2)=C1 HBYXTRBRSLAGLN-UHFFFAOYSA-N 0.000 claims 1
- WUSMFRZBCSILTC-UHFFFAOYSA-N 1-pyridazin-3-yl-1,4-diazepane Chemical compound C1CCNCCN1C1=CC=CN=N1 WUSMFRZBCSILTC-UHFFFAOYSA-N 0.000 claims 1
- RAOIDXGYKMOZET-UHFFFAOYSA-N 3-(1,4-diazepan-1-yl)aniline Chemical compound NC1=CC=CC(N2CCNCCC2)=C1 RAOIDXGYKMOZET-UHFFFAOYSA-N 0.000 claims 1
- FJCDUDLEMKEZCV-UHFFFAOYSA-N 3-(1,4-diazepan-1-yl)phenol Chemical compound OC1=CC=CC(N2CCNCCC2)=C1 FJCDUDLEMKEZCV-UHFFFAOYSA-N 0.000 claims 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 1
- ZQTUUGCDQZHVNP-UHFFFAOYSA-N 3-imidazolidin-1-yl-5-methoxypyridine Chemical compound COC1=CN=CC(N2CNCC2)=C1 ZQTUUGCDQZHVNP-UHFFFAOYSA-N 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- KZISNXPRKLLSJW-UHFFFAOYSA-N 4-(1,4-diazepan-1-yl)isoquinoline Chemical compound C1CCNCCN1C1=CN=CC2=CC=CC=C12 KZISNXPRKLLSJW-UHFFFAOYSA-N 0.000 claims 1
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- CZUOKZHSKPPDOG-UHFFFAOYSA-N N'-(5-methoxypyridin-3-yl)ethane-1,2-diamine Chemical compound COC1=CN=CC(NCCN)=C1 CZUOKZHSKPPDOG-UHFFFAOYSA-N 0.000 claims 1
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 claims 1
Claims (14)
любой из его энантиомеров или любая их смесь, его изотопы или его фармацевтически приемлемая соль, где n равно 1, 2 или 3, m равно 0, 1 или 2, R представляет собой водород, алкил, циклоалкил, циклоалкилалкил или аралкил; и R1 представляет собой аминофенил, нитрофенил, гидроксифенил, алкоксифенил, моноциклическую 5-6-членную гетероциклическую группу, которая может быть замещена один или более чем один раз заместителями, выбранными из группы, состоящей из алкила, циклоалкила, циклоалкилалкила, алкенила, алкинила, алкокси, циклоалкокси, алкенокси, алкинокси, алкинокси, метилендиокси, галогена, СF3, ОСF3, CN, амино, нитро, -COOR3, -CONR2R3, -NH-CO2R2, NHCO-R2, -OCO-NR2R3, где R2 и R3 независимо представляют собой водород или алкил, арила, возможно замещенного один или более чем один раз алкилом, циклоалкилом, циклоалкилалкилом, алкенилом, алкинилом, алкокси, циклоалкокси, алкенокси, алкинокси, метилендиокси, галогеном, СF3, ОСF3, CN, амино и нитро, -Х-алкил-Y-алкила, где Х и Y независимо представляют собой О, S, NH, N-алкил или Se, а алкил возможно замещен алкокси или тиоалкокси, -Х-(алкил)о-арила, где о равно 0 или 1, и Х представляет собой О, S, NH, N-алкил или Se; возможно замещенного один или более чем один раз алкилом, циклоалкилом, циклоалкилалкилом, алкенилом, алкинилом, алкокси, циклоалкокси, алкенокси, алкинокси, метилендиокси, галогеном, СF3, ОСF3, CN, амино и нитро, -Х-(алкил)о-Z, где о равно 0 или 1, а Х представляет собой О, S, NH, N-алкил или Se, и Z представляет собой 5- или 6-членную моноциклическую гетероциклическую группу, возможно замещенную один или более чем один раз алкилом, циклоалкилом, циклоалкилалкилом, алкенилом, алкинилом, алкокси, циклоалкокси, алкенокси, алкинокси, метилендиокси, галогеном, СF3, OCF3, CN, амино и нитро, моноциклической 5-6-членной гетероциклической группы, возможно замещенной один или более чем один раз алкилом, циклоалкилом, циклоалкилалкилом, алкенилом, алкинилом, алкокси, циклоалкокси, алкенокси, алкинокси, метилендиокси, галогеном, СF3, ОСF3, CN, амино и нитро, или R1 представляет собой бициклическую гетероциклическую группу, состоящую из 5-6-членной моноциклической гетероциклической группы, конденсированной с бензольным кольцом, и которая может быть замещена один или более чем один раз заместителями, выбранными из группы, состоящей из алкила, циклоалкила, циклоалкилалкила, алкенила, алкинила, алкокси, алкокси-алкокси, циклоалкокси, алкенокси, алкинокси, метилендиокси, галогена, СF3, ОСF3, CN, амино, нитро, арила, возможно замещенного один или более чем один раз алкилом, циклоалкилом, циклоалкилалкилом, алкенилом, алкинилом, алкокси, циклоалкокси, алкенокси, алкинокси, метилендиокси, галогеном, СF3, ОСF3, CN, амино и нитро; и моноциклической 5-6-членной гетероциклической группы, возможно замещенной один или более чем один раз алкилом, циклоалкилом, циклоалкилалкилом, алкенилом, алкинилом, алкокси, циклоалкокси, алкенокси, алкинокси, метилендиокси, галогеном, СF3, ОСF3, CN, амино и нитро, при условии, что когда R1 представляет собой гидроксифенил, алкоксифенил, нитрофенил или аминофенил, тогда m и n оба не равны 2.1. The compound represented by the General formula
any of its enantiomers or any mixture thereof, its isotopes or its pharmaceutically acceptable salt, where n is 1, 2 or 3, m is 0, 1 or 2, R is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl or aralkyl; and R 1 represents aminophenyl, nitrophenyl, hydroxyphenyl, alkoxyphenyl, a monocyclic 5-6 membered heterocyclic group which may be substituted once or more than once with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, alkynoxy, methylenedioxy, halogen, CF 3 , OCF 3 , CN, amino, nitro, —COOR 3 , —CONR 2 R 3 , —NH — CO 2 R 2 , NHCO-R 2 , - OCO-NR 2 R 3 where R 2 and R 3 independently represent hydrogen or alkyl, aryl, optionally substituted with one or more of yn times with alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino and nitro, -X-alkyl-Y-alkyl wherein X and Y are independently represent O, S, NH, N-alkyl or Se, and the alkyl is optionally substituted with alkoxy or thioalkoxy, -X- (alkyl) o- aryl, where o is 0 or 1, and X represents O, S, NH, N -alkyl or Se; optionally substituted once or more than once with alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF 3 , OCF 3 , CN, amino and nitro, -X- (alkyl) o - Z, where o is 0 or 1, and X is O, S, NH, N-alkyl or Se, and Z is a 5- or 6-membered monocyclic heterocyclic group optionally substituted once or more than once with alkyl, cycloalkyl , cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen m, CF 3 , OCF 3 , CN, amino and nitro, a monocyclic 5-6 membered heterocyclic group optionally substituted once or more than by alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy , halogen, CF 3 , OCF 3 , CN, amino and nitro, or R 1 is a bicyclic heterocyclic group consisting of a 5-6 membered monocyclic heterocyclic group fused to a benzene ring and which may be substituted by one or more than one times alternates selected mi from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, alkoxy-alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF3, OCF3, CN, amino, nitro, aryl optionally substituted with one or more than once by alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF 3 , OCF 3 , CN, amino and nitro; and a monocyclic 5-6 membered heterocyclic group optionally substituted once or more than once by alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF 3 , OCF 3 , CN, amino and nitro, provided that when R 1 is hydroxyphenyl, alkoxyphenyl, nitrophenyl or aminophenyl, then m and n are not equal to 2.
4-метил-1-(3-пиридил)-пиперазин,
4-метил-1-(3-пиридил)-пиперазин,
4-метил-1-(5-метокси-3-пиридил)-пиперазин,
3,5-бис-[4,4'-метил-1,1'-пиперазинил] -пиридин,
1-(5-хлор-3-пиридил)-4-метил-пиперазин,
4-метил-1-(5-фенил-3-пиридил)-пиперазин,
1-(5-этокси-3-пиридил)-4-метил-пиперазин,
1-(5-бутокси-3-пиридил)-4-метил-пиперазин,
4-метил-1-[5-(пропил-1-ен-окси)-3-пиридил] -пиперазин,
1-(5-этенилокси-3-пиридил)-4-метил-пиперазин,
1-(5-метокси-3-пиридил)-4-метил-1,5-диазациклооктан,
1-(6-хлор-3-пиридазинил)-4-метил-1,5-диазациклооктан,
1-(3-пиридил)-пиперазин,
1-(3-пиридил)-пиперазин,
1-(5-метокси-3-пиридил)-пиперазин,
1-(5-хлор-3-пиридил)-пиперазин,
1-(5-фенил-3-пиридил)-пиперазин,
1-(5-метокси-3-пиридил)-1,5-диазациклооктан,
1-(6-хлор-3-пиридазинил)-1,5-диазациклооктан,
1-(6-хлор-3-пиридазинил)-1,4-диазациклооктан,
1-(5-этокси-3-пиридил)-пиперазин,
1-(5-бутокси-3-пиридил)-пиперазин,
1-[5-(пропил-1-ен-окси)-3-пиридил] -пиперазин,
1-(5-этенилокси-3-пиридил)-пиперазин,
1-(5-этокси-3-пиридил)-1,5-диазациклооктан,
1-(5-пропилокси-3-пиридинил)-1,5-диазациклооктан,
1-[5-(пропил-1-ен-окси)-3-пиридил] -1,5-диазациклооктан,
1-(5-этенилокси-3-пиридил)-1,5-диазациклооктан,
1-(5-этокси-3-пиридил)-4-этил-пиперазин,
4-метил-1-(3-пиридил)-гомопиперазин,
4-метил-1-(3-пиридил)-гомопиперазин,
1-(5-метокси-3-пиридил)-4-метил-гомопиперазин,
1-(5-этокси-3-пиридил)-4-метил-гомопиперазин,
4-метил-1-(5-фенил-3-пиридил)-гомопиперазин,
1-(5-бутокси-3-пиридил)-4-метил-гомопиперазин,
1-(5-метоксиэтокси-3-пиридил)-4-метил-гомопиперазин,
4-метил-1-[5-(2-метил-пропилокси)-3-пиридил] -гомопиперазин,
1-(5-циклопропилметокси-3-пиридил)-4-метил-гомопиперазин,
4-метил-1-(5-пропилокси-3-пиридил)-гомопиперазин,
1-(5-гексилокси-3-пиридил)-4-метил-гомопиперазин,
4-метил-1-[5-(3-метил-бутокси)-3-пиридил] -гомопиперазин,
4-метил-1-(6-тиоэтокси-3-пиридил)-гомопиперазин,
1-(5-циклогексилметокси-3-пиридил)-4-метил-гомопиперазин,
4-метил-1-(5-пентилокси-3-пиридил)-гомопиперазин,
1-(5-гептилокси-3-пиридил)-4-метил-гомопиперазин,
4-метил-1-(5-пропил-1-ен-окси-3-пиридил)-гомопиперазин,
4-метил-1-(5-тиобензил-3-пиридил)-гомопиперазин,
4-метил-1-[5-(3-пиридил)-3-пиридил] -гомопиперазин,
4-метил-1-(3-нитрофенил)-гомопиперазин,
4-метил-1-(6-хлор-3-пиридазинил)-гомопиперазин,
4-метил-1-(6-фенил-3-пиридазинил)-гомопиперазин,
4-метил-1-(3-пиридазинил)-гомопиперазин,
4-метил-1-(6-метил-3-пиридазинил)-гомопиперазин,
1-(5-циклопентилокси-3-пиридил)-4-метил-гомопиперазин,
4-бензил-1-(3-пиридил)-гомопиперазин,
4-этил-1-(3-пиридил)-гомопиперазин,
1-(3-пиридил)-гомопиперазин,
1-(3-пиридил)-гомопиперазин,
1-(6-метокси-3-пиридил)-гомопиперазин,
1-(2-хлор-5-метокси-3-пиридил)-гомопиперазин,
1-(6-хлор-5-метокси-3-пиридил)-гомопиперазин,
1-(6-бром-5-этокси-3-пиридил)-гомопиперазин,
1-[6-(N-пирролидинил)-3-пиридил] -гомопиперазин,
1-(6-фенил-3-пиридил)-4-гомопиперазин,
1-[5-(3-нитрофенил)-3-пиридил] -4-гомопиперазин,
1-(5-метокси-3-пиридил)-гомопиперазин,
1-(5-фенил-3-пиридил)-гомопиперазин,
1-(5-этокси-3-пиридил)-гомопиперазин,
1-(5-бутокси-3-пиридил)-гомопиперазин,
1-(5-метоксиэтокси-3-пиридил)-гомопиперазин,
1-[5-(2-метил-пропокси)-3-пиридил] -гомопиперазин,
1-[5-(2-гидрокси-этокси)-3-пиридил] -гомопиперазин,
1-[5-(3-метил-бутокси)-3-пиридил] -гомопиперазин,
1-(5-циклопропилметокси-3-пиридил)-гомопиперазин,
1-(5-пропилокси-3-пиридил)-гомопиперазин,
1-(5-гексилокси-3-пиридил)-гомопиперазин,
1-(5-циклогексилметокси-3-пиридил)-гомопиперазин,
1-(6-тиоэтокси-3-пиридил)-гомопиперазин,
1-[5-(2-этокси-этокси)-3-пиридил] -гомопиперазин,
1-(5-пентилокси-3-пиридил)-гомопиперазин,
1-(5-гептилокси-3-пиридил)-гомопиперазин,
1-[5-(пропил-1-ен-окси)-3-пиридил] -гомопиперазин,
1-(5-тиобензил-3-пиридил)-гомопиперазин,
1-(5-карбоксиламидо-3-пиридил)-гомопиперазин,
1-(5-тиофенил-3-пиридил)-гомопиперазин,
1-[(5-метокси-метокси)-3-пиридил] -гомопиперазин,
1-[5-(3-пиридил)-3-пиридил] -гомопиперазин,
1-(5-(1-пирролил)-3-пиридил)-гомопиперазин,
1-(5-(1-индолил)-3-пиридил)-гомопиперазин,
1-(5,6-диметокси-3-пиридил)-гомопиперазин,
1-(5-этенилокси-3-пиридил)-гомопиперазин,
1-(5-циклопентилокси-3-пиридил)-гомопиперазин,
1-[5-(этокси-d5)-3-пиридил] -гомопиперазин,
1-(3-хлор-5-пиридил)-гомопиперазин,
1-(3-бром-5-пиридил)-гомопиперазин,
1-(4-изохинолинил)-гомопиперазин,
1-(5-гидрокси-3-пиридил)-гомопиперазин,
1-(5-трифторометансульфонил-окси-3-пиридил)-гомопиперазин,
1-(5-этинил-3-пиридил)-гомопиперазин,
1-(3-нитрофенил)-гомопиперазин,
1-(3-аминофенил)-гомопиперазин,
1-(3-метоксифенил)-гомопиперазин,
1-(3-гидроксифенил)-гомопиперазин,
1-(6-хлор-3-пиридазинил)-гомопиперазин,
1-(6-фенил-3-пиридазинил)-гомопиперазин,
1-(6-хлор-2-пиразинил)-гомопиперазин,
1-(3,6-диметил-2-пиразинил)-гомопиперазин,
1-(6-метил-3-пиридазинил)-гомопиперазин,
1-(5-трифторметил-3-пиридил)-гомопиперазин,
1-(6-бром-3-пиридил)-гомопиперазин,
1-(6-хлор-3-пиридил)-гомопиперазин,
1-(3-пиридазинил)-гомопиперазин,
N-(5-метокси-3-пиридил)-этилендиамин,
1-(5-метокси-3-пиридил)-имидазолидин,
1-(5-метокси-3-пиридил)-1,3-диазациклогексан,
или их фармацевтически приемлемую соль присоединения.6. The compound of formula (I) according to claim 1, wherein said compound is:
4-methyl-1- (3-pyridyl) piperazine,
4-methyl-1- (3-pyridyl) piperazine,
4-methyl-1- (5-methoxy-3-pyridyl) piperazine,
3,5-bis- [4,4'-methyl-1,1'-piperazinyl] pyridine,
1- (5-chloro-3-pyridyl) -4-methyl-piperazine,
4-methyl-1- (5-phenyl-3-pyridyl) piperazine,
1- (5-ethoxy-3-pyridyl) -4-methyl-piperazine,
1- (5-butoxy-3-pyridyl) -4-methyl-piperazine,
4-methyl-1- [5- (propyl-1-en-hydroxy) -3-pyridyl] piperazine,
1- (5-ethenyloxy-3-pyridyl) -4-methyl-piperazine,
1- (5-methoxy-3-pyridyl) -4-methyl-1,5-diazacyclooctane,
1- (6-chloro-3-pyridazinyl) -4-methyl-1,5-diazacyclooctane,
1- (3-pyridyl) piperazine,
1- (3-pyridyl) piperazine,
1- (5-methoxy-3-pyridyl) piperazine,
1- (5-chloro-3-pyridyl) piperazine,
1- (5-phenyl-3-pyridyl) piperazine,
1- (5-methoxy-3-pyridyl) -1,5-diazacyclooctane,
1- (6-chloro-3-pyridazinyl) -1,5-diazacyclooctane,
1- (6-chloro-3-pyridazinyl) -1,4-diazacyclooctane,
1- (5-ethoxy-3-pyridyl) piperazine,
1- (5-butoxy-3-pyridyl) piperazine,
1- [5- (propyl-1-en-hydroxy) -3-pyridyl] piperazine,
1- (5-ethenyloxy-3-pyridyl) piperazine,
1- (5-ethoxy-3-pyridyl) -1,5-diazacyclooctane,
1- (5-propyloxy-3-pyridinyl) -1,5-diazacyclooctane,
1- [5- (propyl-1-en-hydroxy) -3-pyridyl] -1,5-diazacyclooctane,
1- (5-ethenyloxy-3-pyridyl) -1,5-diazacyclooctane,
1- (5-ethoxy-3-pyridyl) -4-ethyl-piperazine,
4-methyl-1- (3-pyridyl) -homopiperazine,
4-methyl-1- (3-pyridyl) -homopiperazine,
1- (5-methoxy-3-pyridyl) -4-methyl-homopiperazine,
1- (5-ethoxy-3-pyridyl) -4-methyl-homopiperazine,
4-methyl-1- (5-phenyl-3-pyridyl) homopiperazine,
1- (5-butoxy-3-pyridyl) -4-methyl-homopiperazine,
1- (5-methoxyethoxy-3-pyridyl) -4-methyl-homopiperazine,
4-methyl-1- [5- (2-methyl-propyloxy) -3-pyridyl] homopiperazine,
1- (5-cyclopropylmethoxy-3-pyridyl) -4-methyl-homopiperazine,
4-methyl-1- (5-propyloxy-3-pyridyl) homopiperazine,
1- (5-hexyloxy-3-pyridyl) -4-methyl-homopiperazine,
4-methyl-1- [5- (3-methyl-butoxy) -3-pyridyl] homopiperazine,
4-methyl-1- (6-thioethoxy-3-pyridyl) homopiperazine,
1- (5-cyclohexylmethoxy-3-pyridyl) -4-methyl-homopiperazine,
4-methyl-1- (5-pentyloxy-3-pyridyl) homopiperazine,
1- (5-heptyloxy-3-pyridyl) -4-methyl-homopiperazine,
4-methyl-1- (5-propyl-1-en-hydroxy-3-pyridyl) homopiperazine,
4-methyl-1- (5-thiobenzyl-3-pyridyl) -homopiperazine,
4-methyl-1- [5- (3-pyridyl) -3-pyridyl] homopiperazine,
4-methyl-1- (3-nitrophenyl) homopiperazine,
4-methyl-1- (6-chloro-3-pyridazinyl) homopiperazine,
4-methyl-1- (6-phenyl-3-pyridazinyl) homopiperazine,
4-methyl-1- (3-pyridazinyl) homopiperazine,
4-methyl-1- (6-methyl-3-pyridazinyl) homopiperazine,
1- (5-cyclopentyloxy-3-pyridyl) -4-methyl-homopiperazine,
4-benzyl-1- (3-pyridyl) -homopiperazine,
4-ethyl-1- (3-pyridyl) -homopiperazine,
1- (3-pyridyl) -homopiperazine,
1- (3-pyridyl) -homopiperazine,
1- (6-methoxy-3-pyridyl) homopiperazine,
1- (2-chloro-5-methoxy-3-pyridyl) homopiperazine,
1- (6-chloro-5-methoxy-3-pyridyl) homopiperazine,
1- (6-bromo-5-ethoxy-3-pyridyl) -homopiperazine,
1- [6- (N-pyrrolidinyl) -3-pyridyl] -homopiperazine,
1- (6-phenyl-3-pyridyl) -4-homopiperazine,
1- [5- (3-nitrophenyl) -3-pyridyl] -4-homopiperazine,
1- (5-methoxy-3-pyridyl) -homopiperazine,
1- (5-phenyl-3-pyridyl) homopiperazine,
1- (5-ethoxy-3-pyridyl) homopiperazine,
1- (5-butoxy-3-pyridyl) -homopiperazine,
1- (5-methoxyethoxy-3-pyridyl) -homopiperazine,
1- [5- (2-methyl-propoxy) -3-pyridyl] -homopiperazine,
1- [5- (2-hydroxy-ethoxy) -3-pyridyl] homopiperazine,
1- [5- (3-methyl-butoxy) -3-pyridyl] -homopiperazine,
1- (5-cyclopropylmethoxy-3-pyridyl) -homopiperazine,
1- (5-propyloxy-3-pyridyl) -homopiperazine,
1- (5-hexyloxy-3-pyridyl) -homopiperazine,
1- (5-cyclohexylmethoxy-3-pyridyl) -homopiperazine,
1- (6-thioethoxy-3-pyridyl) -homopiperazine,
1- [5- (2-ethoxy-ethoxy) -3-pyridyl] -homopiperazine,
1- (5-pentyloxy-3-pyridyl) -homopiperazine,
1- (5-heptyloxy-3-pyridyl) -homopiperazine,
1- [5- (propyl-1-en-hydroxy) -3-pyridyl] -homopiperazine,
1- (5-thiobenzyl-3-pyridyl) -homopiperazine,
1- (5-carboxylamido-3-pyridyl) -homopiperazine,
1- (5-thiophenyl-3-pyridyl) -homopiperazine,
1 - [(5-methoxy-methoxy) -3-pyridyl] -homopiperazine,
1- [5- (3-pyridyl) -3-pyridyl] homopiperazine,
1- (5- (1-pyrrolyl) -3-pyridyl) homopiperazine,
1- (5- (1-indolyl) -3-pyridyl) homopiperazine,
1- (5,6-dimethoxy-3-pyridyl) -homopiperazine,
1- (5-ethenyloxy-3-pyridyl) -homopiperazine,
1- (5-cyclopentyloxy-3-pyridyl) homopiperazine,
1- [5- (ethoxy-d5) -3-pyridyl] homopiperazine,
1- (3-chloro-5-pyridyl) homopiperazine,
1- (3-bromo-5-pyridyl) -homopiperazine,
1- (4-isoquinolinyl) -homopiperazine,
1- (5-hydroxy-3-pyridyl) homopiperazine,
1- (5-trifluoromethanesulfonyl-hydroxy-3-pyridyl) -homopiperazine,
1- (5-ethynyl-3-pyridyl) -homopiperazine,
1- (3-nitrophenyl) -homopiperazine,
1- (3-aminophenyl) -homopiperazine,
1- (3-methoxyphenyl) -homopiperazine,
1- (3-hydroxyphenyl) -homopiperazine,
1- (6-chloro-3-pyridazinyl) homopiperazine,
1- (6-phenyl-3-pyridazinyl) homopiperazine,
1- (6-chloro-2-pyrazinyl) homopiperazine,
1- (3,6-dimethyl-2-pyrazinyl) homopiperazine,
1- (6-methyl-3-pyridazinyl) homopiperazine,
1- (5-trifluoromethyl-3-pyridyl) -homopiperazine,
1- (6-bromo-3-pyridyl) -homopiperazine,
1- (6-chloro-3-pyridyl) homopiperazine,
1- (3-pyridazinyl) -homopiperazine,
N- (5-methoxy-3-pyridyl) ethylenediamine,
1- (5-methoxy-3-pyridyl) imidazolidine,
1- (5-methoxy-3-pyridyl) -1,3-diazacyclohexane,
or a pharmaceutically acceptable addition salt thereof.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK122597 | 1997-10-27 | ||
DK1225/97 | 1997-10-27 | ||
DK0409/98 | 1998-03-24 | ||
DK40998 | 1998-03-24 | ||
DKPA199800796 | 1998-06-19 | ||
DK79698 | 1998-06-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000110744A true RU2000110744A (en) | 2002-05-10 |
RU2205179C2 RU2205179C2 (en) | 2003-05-27 |
Family
ID=27220661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000110744/04A RU2205179C2 (en) | 1997-10-27 | 1998-10-27 | Homopiperazine derivative and pharmaceutical composition |
Country Status (26)
Country | Link |
---|---|
US (2) | US6825189B1 (en) |
EP (2) | EP1027336B1 (en) |
JP (1) | JP4570773B2 (en) |
KR (1) | KR100607838B1 (en) |
CN (1) | CN1131211C (en) |
AT (2) | ATE278670T1 (en) |
AU (1) | AU744539B2 (en) |
BR (1) | BR9813279B1 (en) |
CA (1) | CA2306093C (en) |
CZ (1) | CZ299499B6 (en) |
DE (2) | DE69842058D1 (en) |
DK (1) | DK1027336T3 (en) |
EE (1) | EE04588B1 (en) |
ES (1) | ES2230723T3 (en) |
HK (1) | HK1031378A1 (en) |
HU (1) | HU226859B1 (en) |
IL (2) | IL135108A0 (en) |
IS (1) | IS5420A (en) |
NO (1) | NO317094B1 (en) |
NZ (1) | NZ503520A (en) |
PL (1) | PL203140B1 (en) |
PT (1) | PT1027336E (en) |
RU (1) | RU2205179C2 (en) |
SK (1) | SK285198B6 (en) |
TR (1) | TR200001171T2 (en) |
WO (1) | WO1999021834A1 (en) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
HU226859B1 (en) * | 1997-10-27 | 2009-12-28 | Neurosearch As | Phenyl- or heteroaryl-homopiperazines, their use and medicaments containing them |
JP2002543070A (en) | 1999-04-26 | 2002-12-17 | ニューロサーチ、アクティーゼルスカブ | Heteroaryldiazacycloalkanes, their production and use |
EP1177196B1 (en) | 1999-05-04 | 2004-03-10 | Neurosearch A/S | Heteroaryl diazabicycloalkanes, their preparation and use |
GB9914026D0 (en) * | 1999-06-17 | 1999-08-18 | Zeneca Ltd | Chemical compounds |
DE60018312T2 (en) | 1999-12-14 | 2005-08-18 | Neurosearch A/S | NEW HETEROARYL DIAZABIZYKLOALKANE |
US6809105B2 (en) | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
MY145722A (en) * | 2000-04-27 | 2012-03-30 | Abbott Lab | Diazabicyclic central nervous system active agents |
ATE334979T1 (en) * | 2000-10-13 | 2006-08-15 | Neurosearch As | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE |
CA2341952A1 (en) | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
US8039459B2 (en) | 2004-07-15 | 2011-10-18 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
US8557804B2 (en) | 2002-03-25 | 2013-10-15 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
NZ537214A (en) | 2002-07-05 | 2007-08-31 | Targacept Inc | N-Aryl diazaspiracyclic compounds capable of affecting nicotinic cholinergic receptors and methods of preparation and use thereof |
WO2004009775A2 (en) | 2002-07-19 | 2004-01-29 | Targacept, Inc. | Methods and compositions relating to chimeric nicotinic receptor subunits |
US7098331B2 (en) | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
CA2539811A1 (en) | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
JP5254616B2 (en) | 2004-09-13 | 2013-08-07 | クロノ セラピューティクス、インコーポレイテッド | Biosynchronous transdermal drug delivery |
US20080167321A1 (en) * | 2004-09-20 | 2008-07-10 | Xenon Pharmaceuticals Inc. | Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase |
EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
CN101084212A (en) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase |
CN101084207A (en) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
US7592343B2 (en) | 2004-09-20 | 2009-09-22 | Xenon Pharmaceuticals Inc. | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors |
MX2007003321A (en) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents. |
WO2006034440A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
US7384929B2 (en) | 2004-09-20 | 2008-06-10 | Targacept, Inc. | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
UA88792C2 (en) | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Hydroxybenzoate salts of metanicotine compounds |
KR20070097590A (en) * | 2005-01-25 | 2007-10-04 | 에픽스 델라웨어, 인코포레이티드 | Substituted arylamine compounds and their use as 5-ht6 modulators |
FR2885615B1 (en) | 2005-05-12 | 2007-06-22 | Servier Lab | NOVEL PHENYLPYRIDINYLPIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2885616B1 (en) | 2005-05-12 | 2007-06-22 | Servier Lab | NOVEL PHENYLPYRIDINYLPIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
CN101208089A (en) | 2005-06-03 | 2008-06-25 | 泽农医药公司 | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
FR2889188B1 (en) * | 2005-07-28 | 2007-09-07 | Servier Lab | NOVEL POLYSUBSTITUTED 1,1-PYRIDINYLAMINOCYCLOPROPANAMINE COMPOUNDS, PROCESS FOR PREPARING THEM AND PHAMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO2007024814A1 (en) | 2005-08-22 | 2007-03-01 | Targacept, Inc. | HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF |
US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
CN101528698A (en) | 2006-05-09 | 2009-09-09 | 阿斯利康公司 | Novel salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
TWI389889B (en) | 2006-05-09 | 2013-03-21 | Targacept Inc | Novel polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
WO2007137955A1 (en) * | 2006-05-30 | 2007-12-06 | F. Hoffmann-La Roche Ag | Piperidinyl pyrimidine derivatives |
WO2008028903A2 (en) | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
EP2322166A1 (en) | 2007-04-02 | 2011-05-18 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
CA2687931C (en) * | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
WO2009046025A1 (en) | 2007-10-01 | 2009-04-09 | Comentis, Inc. | Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease |
US8697722B2 (en) * | 2007-11-02 | 2014-04-15 | Sri International | Nicotinic acetylcholine receptor modulators |
PE20120061A1 (en) | 2008-12-19 | 2012-02-19 | Boehringer Ingelheim Int | PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR2 RECEPTOR |
EP2509982A1 (en) | 2009-12-07 | 2012-10-17 | Targacept, Inc. | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands |
PT3091012T (en) | 2009-12-17 | 2018-06-27 | Centrexion Therapeutics Corp | Ccr2 receptor antagonists and uses thereof |
CA2787063C (en) | 2010-01-11 | 2018-11-27 | Astraea Therapeutics, Llc | Nicotinic acetylcholine receptor modulators |
JP5675850B2 (en) | 2010-02-05 | 2015-02-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Hetaryl- [1,8] naphthyridine derivatives |
US20110256064A1 (en) * | 2010-04-16 | 2011-10-20 | Ac Immune, S.A. | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins |
US8946218B2 (en) | 2010-05-12 | 2015-02-03 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
JP2013526507A (en) | 2010-05-12 | 2013-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | NOVEL CCR2 RECEPTOR ANTAGONIST, PROCESS FOR PRODUCING THE SAME AND USE THEREOF AS DRUG |
US8841313B2 (en) | 2010-05-17 | 2014-09-23 | Boehringer Ingelheim International Gmbh | CCR2 antagonists and uses thereof |
WO2011146009A1 (en) | 2010-05-20 | 2011-11-24 | Targacept Inc. | New process for the preparation of aryl substituted olefinic amines |
JP5636094B2 (en) | 2010-05-25 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | CCR2 receptor antagonist |
EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
WO2012105815A2 (en) * | 2011-02-01 | 2012-08-09 | 전북대학교산학협력단 | Biodegradable paox microspheres having cationic properties |
JP5786258B2 (en) | 2011-07-15 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel and selective CCR2 antagonist |
CN102924390B (en) * | 2012-09-07 | 2014-12-31 | 苏州康润医药有限公司 | Synthetic method of 1,5-diazacyclooctane-1-tert-butyl ester formate |
WO2016007630A1 (en) | 2014-07-11 | 2016-01-14 | Alpharmagen, Llc | Quinuclidine compounds for modulating alpha7 -nicotinic acetylcholine receptor activity |
CA2974324A1 (en) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Drug delivery methods and systems |
MX2017017177A (en) | 2015-07-02 | 2018-11-09 | Centrexion Therapeutics Corp | (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)pi peridin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro- 2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate. |
AU2018205529B2 (en) | 2017-01-06 | 2023-08-10 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
JP7420797B2 (en) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | Drug delivery methods and systems |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2985657A (en) * | 1959-10-12 | 1961-05-23 | Paul A J Janssen | 1-(aroylalkyl)-4-heterocyclylpiperazines |
JPS536156B2 (en) * | 1972-10-30 | 1978-03-04 | ||
US4017622A (en) | 1972-12-18 | 1977-04-12 | Dainippon Pharmaceutical Co., Ltd. | Piperazine derivatives |
AT330777B (en) | 1973-09-08 | 1976-07-26 | Thomae Gmbh Dr K | PROCESS FOR THE PREPARATION OF NEW ISOCHINOLINE DERIVATIVES AND THEIR SALTS |
DK143899C (en) * | 1975-04-21 | 1982-04-13 | Merck & Co Inc | ANALOGY PROCEDURE FOR PREPARATION OF PIPERAZINYLPYRAZINE DERIVATIVES |
US3994898A (en) * | 1975-10-16 | 1976-11-30 | E. R. Squibb & Sons, Inc. | 1,2,4-Triazolo (4,3-b) pyridazin-3-ones |
NL171985C (en) * | 1976-02-10 | 1983-06-16 | Rhone Poulenc Ind | METHOD FOR PREPARING PREPARATIONS WITH ACTION AGAINST SCHISTOSOMIASIS, THE PREPARED PREPARATIONS SO GIVEN AND METHOD FOR PREPARING 1,2-DITHIOOL COMPOUNDS. |
GB1542030A (en) * | 1976-08-19 | 1979-03-14 | Sterling Drug Inc | Cyclic alkylidenyl n-(pyridazinyl)aminomethylenemalomates and their preparation |
DE2708187A1 (en) * | 1977-02-25 | 1978-08-31 | Thomae Gmbh Dr K | Piperazinyl-(hydroxy)propyl derivs. of pyrido-pyridazine cpds. - with hypotensive activity and effects on heart rate and cardiac contraction |
HU176972B (en) * | 1977-06-13 | 1981-06-28 | Gyogyszerkutato Intezet | Process for producing new piridazinyl-hydrasone derivatives |
US4163849A (en) * | 1978-03-17 | 1979-08-07 | Merck & Co., Inc. | Piperazinylpyrazines |
US4179563A (en) * | 1978-05-19 | 1979-12-18 | Warner-Lambert Company | 3-Aryloxy-substituted-aminopyridines and methods for their production |
JPS5618983A (en) * | 1979-07-25 | 1981-02-23 | Eisai Co Ltd | Theophylline derivative and its preapration |
US4251530A (en) | 1980-02-19 | 1981-02-17 | Merck & Co., Inc. | 2-{[4-(6-Substituted-2-pyrazinyl)-1-piperazinyl]alkyl}-5-substituted-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one analgesic agents |
DE3034001A1 (en) * | 1980-09-10 | 1982-04-22 | Hoechst Ag, 6000 Frankfurt | ISOCHINOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING IT AND THEIR USE |
FI70411C (en) * | 1980-12-29 | 1986-09-19 | Pfizer | FORM OF ANTHYPERTENSIVE 4-AMINO-6,7-DIMETOXY-2-PIPERAZINOQUINAZOLE DERIVATIVES |
PL147465B1 (en) * | 1984-03-26 | 1989-06-30 | Janssen Pharmaceutica Nv | Method of obtaining novel pyridazionoamine compounds |
US5001125A (en) * | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
ES8802151A1 (en) * | 1985-07-31 | 1988-04-01 | Janssen Pharmaceutica Nv | Novel (4-substituted-piperazinyl)pyridazines. |
GB8603120D0 (en) * | 1986-02-07 | 1986-03-12 | Pfizer Ltd | Anti-dysrhythmia agents |
GB8609630D0 (en) * | 1986-04-19 | 1986-05-21 | Pfizer Ltd | Anti-arrhythmia agents |
SE8701375D0 (en) | 1987-04-02 | 1987-04-02 | Leo Ab | NOVEL PYRIDYL AND PYRIMIDYL DERIVATIVES |
MY104343A (en) * | 1987-11-23 | 1994-03-31 | Janssen Pharmaceutica Nv | Novel pyridizinamine deravatives |
US4876256A (en) | 1988-04-29 | 1989-10-24 | Merck & Co., Inc. | Alkylpiperazinylpyridines as hypoglycemic agents |
SE8803429D0 (en) | 1988-09-28 | 1988-09-28 | Pharmacia Ab | NOVEL PYRIDYL AND PYRIMIDYL DERIVATIVES |
US5019574A (en) * | 1988-09-30 | 1991-05-28 | Chugai Seiyaku Kabushiki Kaisha | 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function |
JPH02167265A (en) * | 1988-09-30 | 1990-06-27 | Chugai Pharmaceut Co Ltd | Novel 3,4-diaminoquinoline and pyridine-based compound |
DE68912282T2 (en) | 1988-11-24 | 1994-04-28 | Akzo Nv | Pharmaceutical compositions containing 1- [mono- or bis (trifluoromethyl) -2-pyridinyl] piperazines. |
JP2843632B2 (en) * | 1989-03-01 | 1999-01-06 | 日清製粉株式会社 | Pyridinecarboxamide derivatives |
US4994456A (en) * | 1989-03-01 | 1991-02-19 | Nisshin Flour Milling Co., Ltd. | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same |
NZ233526A (en) * | 1989-05-15 | 1991-09-25 | Janssen Pharmaceutica Nv | Pyridazine derivatives and their pharmaceutical compositions |
CA2071529C (en) * | 1989-12-28 | 2001-03-20 | Donna Lee Romero | Diaromatic substituted anti-aids compounds |
KR100236808B1 (en) * | 1991-07-03 | 2000-02-01 | 로렌스 티. 마이젠헬더 | Substituted indoles as anti-aids pharmaceuticals |
JPH05345764A (en) * | 1991-11-26 | 1993-12-27 | Asahi Chem Ind Co Ltd | New azepine derivative. its production and use |
SE9201239D0 (en) | 1992-04-21 | 1992-04-21 | Kabi Pharmacia Ab | AGENTS FOR TREATING SUBSTANCE ABUSE DISORDERS |
TW279864B (en) * | 1993-02-19 | 1996-07-01 | Janssen Pharmaceutica Nv | |
CA2156064A1 (en) * | 1993-03-17 | 1994-09-29 | Megumi Kawai | Substituted alicyclic amine-containing macrocyclic immunomodulators |
GB9408185D0 (en) * | 1994-04-25 | 1994-06-15 | Fujisawa Pharmaceutical Co | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same |
US5607936A (en) * | 1994-09-30 | 1997-03-04 | Merck & Co., Inc. | Substituted aryl piperazines as neurokinin antagonists |
EP0793662A1 (en) | 1994-11-23 | 1997-09-10 | Neurogen Corporation | Aminomethyl aryl compounds; dopamine receptor subtype selective ligands |
AU717744B2 (en) * | 1996-01-15 | 2000-03-30 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
US5929281A (en) * | 1996-04-19 | 1999-07-27 | Tosoh Corporation | Process for producing heterocyclic aromatic amine or arylamine |
SE9601708D0 (en) | 1996-05-06 | 1996-05-06 | Pharmacia Ab | Pyridyl and pyrimidyl piperazines in the treatment of substance abuse disorders |
GB9614236D0 (en) * | 1996-07-06 | 1996-09-04 | Zeneca Ltd | Chemical compounds |
JP3216566B2 (en) * | 1996-07-15 | 2001-10-09 | 東ソー株式会社 | Method for producing heterocyclic aromatic amines |
AU5343498A (en) * | 1997-01-21 | 1998-08-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thiophene compounds and medicinal use thereof |
DE19724980A1 (en) * | 1997-06-13 | 1998-12-17 | Basf Ag | 3-Substituted 3,4-dihydro-thieno [2,3-d] pyrimidine derivatives, their preparation and use |
WO1999009025A2 (en) * | 1997-08-15 | 1999-02-25 | Pfizer Products Inc. | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor |
DE69829875T2 (en) * | 1997-10-14 | 2006-03-09 | Mitsubishi Pharma Corp. | PIPERAZINE COMPOUNDS AND ITS MEDICAL USE |
HU226859B1 (en) * | 1997-10-27 | 2009-12-28 | Neurosearch As | Phenyl- or heteroaryl-homopiperazines, their use and medicaments containing them |
GB9726736D0 (en) | 1997-12-18 | 1998-02-18 | Zeneca Ltd | Chemical compounds |
-
1998
- 1998-10-27 HU HU0100426A patent/HU226859B1/en not_active IP Right Cessation
- 1998-10-27 CA CA2306093A patent/CA2306093C/en not_active Expired - Fee Related
- 1998-10-27 DE DE69842058T patent/DE69842058D1/en not_active Expired - Lifetime
- 1998-10-27 DK DK98951286T patent/DK1027336T3/en active
- 1998-10-27 WO PCT/DK1998/000465 patent/WO1999021834A1/en active IP Right Grant
- 1998-10-27 AT AT98951286T patent/ATE278670T1/en active
- 1998-10-27 TR TR2000/01171T patent/TR200001171T2/en unknown
- 1998-10-27 RU RU2000110744/04A patent/RU2205179C2/en not_active IP Right Cessation
- 1998-10-27 DE DE69826883T patent/DE69826883T2/en not_active Expired - Lifetime
- 1998-10-27 AU AU97368/98A patent/AU744539B2/en not_active Ceased
- 1998-10-27 ES ES98951286T patent/ES2230723T3/en not_active Expired - Lifetime
- 1998-10-27 KR KR1020007004495A patent/KR100607838B1/en not_active IP Right Cessation
- 1998-10-27 EP EP98951286A patent/EP1027336B1/en not_active Expired - Lifetime
- 1998-10-27 PL PL340224A patent/PL203140B1/en not_active IP Right Cessation
- 1998-10-27 NZ NZ503520A patent/NZ503520A/en unknown
- 1998-10-27 CZ CZ20001507A patent/CZ299499B6/en not_active IP Right Cessation
- 1998-10-27 JP JP2000517946A patent/JP4570773B2/en not_active Expired - Fee Related
- 1998-10-27 EE EEP200000178A patent/EE04588B1/en not_active IP Right Cessation
- 1998-10-27 IL IL13510898A patent/IL135108A0/en active IP Right Grant
- 1998-10-27 SK SK614-2000A patent/SK285198B6/en not_active IP Right Cessation
- 1998-10-27 EP EP04102866A patent/EP1491532B1/en not_active Expired - Lifetime
- 1998-10-27 BR BRPI9813279-2A patent/BR9813279B1/en not_active IP Right Cessation
- 1998-10-27 CN CN98810601A patent/CN1131211C/en not_active Expired - Fee Related
- 1998-10-27 PT PT98951286T patent/PT1027336E/en unknown
- 1998-10-27 AT AT04102866T patent/ATE491689T1/en not_active IP Right Cessation
-
2000
- 2000-03-16 IL IL135108A patent/IL135108A/en not_active IP Right Cessation
- 2000-03-17 US US09/528,176 patent/US6825189B1/en not_active Expired - Fee Related
- 2000-03-28 IS IS5420A patent/IS5420A/en unknown
- 2000-04-26 NO NO20002132A patent/NO317094B1/en not_active IP Right Cessation
-
2001
- 2001-03-26 HK HK01102152A patent/HK1031378A1/en not_active IP Right Cessation
-
2003
- 2003-10-03 US US10/677,240 patent/US6897219B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000110744A (en) | Heteroaryl diazacycloalkanes as cholinergic ligands for nicotinic acetylcholine receptors | |
CA2306093A1 (en) | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors | |
DE60131844T2 (en) | 2-AMINO-3- (ALKYL) -PYRIMIDONE DERIVATIVES AS GSK3.BETA. HEMMER | |
DE60018037T2 (en) | SUBSTITUTED 2-ARYL-3- (HETEROARYL) -IMIDAZO [1,2-ALPHA] PYRIMIDINE AND ITS RELATED MEDICAMENT AND METHOD | |
JP2001521025A5 (en) | ||
AU2014288116B2 (en) | P2X4 receptor antagonist | |
HRP20080359B1 (en) | Hiv replication inhibiting pyrimidines | |
CN102123988B (en) | Squaric acid derivatives as inhibitors of nicotinamide | |
CN103328468A (en) | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease | |
CN101022801A (en) | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | |
CA2366857A1 (en) | Phthalazine derivatives for treating inflammatory diseases | |
CN105407888A (en) | Novel bicyclic bromodomain inhibitors | |
AU2012345557A1 (en) | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | |
RU2007102429A (en) | Pyrimidine urea derivatives as kinase inhibitors | |
RU2006105716A (en) | Pyridazine derivatives and their use as therapeutic agents | |
MXPA05006869A (en) | Benzoazolypiperazine derivatives having mglur1- and mglur5-antagonistic activity. | |
CA2463821A1 (en) | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | |
DE60235500D1 (en) | SELECTIVE PYRIMIDINE A2B ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | |
RU2015137615A (en) | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | |
CN108602821A (en) | 1H- imidazos [4,5-B] pyridyl group and 2- oxos -2,3- dihydro -1H- imidazos [4,5-B] pyridinyl heterocycle BET bromine structural domain inhibitor | |
EP2389197A1 (en) | Combinations comprising methotrexate and dhodh inhibitors | |
CA2551529A1 (en) | Amide derivative and medicine | |
EA006552B1 (en) | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor | |
US20040077661A1 (en) | Treatment of tuberous sclerosis associated neoplasms | |
AU2018204290A1 (en) | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |